Helus Pharma to Participate in H.C. Wainwright Conference

Helus Pharma, a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health, will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York City. The company announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will engage in a fireside chat on Monday, September 14, 2026, at 9:00 a.m. EDT.

The conference, which runs from September 14 to 16, 2026, is expected to attract a wide array of investors and industry professionals. Helus Pharma’s participation highlights the company’s ongoing efforts to attract financial support and showcase its progress in the development of innovative treatments for mental health conditions.

Helus Pharma is currently advancing its lead product, HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. The company has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for this program. Additionally, HLP004, a proprietary NSA in Phase 2 development, is being evaluated for the treatment of generalized anxiety disorder.

The company’s commitment to mental health innovation is underscored by its extensive research portfolio. Helus Pharma’s proprietary NSAs are designed to activate serotonin pathways, which are believed to promote neuroplasticity and offer durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland, and has established a reputation for its innovative drug discovery and delivery platforms.

Halstead commented, “Our participation in the H.C. Wainwright conference is a significant milestone for Helus Pharma. It provides us with a valuable platform to engage with potential investors and share our progress with the broader investment community. We are excited to highlight the potential of our proprietary NSAs in addressing the growing unmet needs in mental health treatment.”

The company’s forward-looking statements indicate that it aims to improve the treatment landscape for mental health conditions through the introduction of NSAs. Helus Pharma’s plans include the engineering of novel formulation approaches and treatment regimens to provide effective and durable improvements in mental health.

With a growing focus on mental health innovation, Helus Pharma’s participation in the conference is likely to attract significant attention from investors and industry experts. The company’s ongoing clinical trials and breakthrough designations suggest a promising future for its proprietary NSAs in the treatment of mental health disorders.